JS004 , Recombinant humanized IgG4k monoclonal antibody specific to BTLA for injection Intravenous infusion

BIOLOGICAL2 trials

Sponsors

Shanghai Junshi Bioscience Co., Ltd.

Conditions

Head and Neck Squamous Cell CarcinomNasopharyngeal CarcinomaRecurrent/Refractory Malignant Lymphoma

Phase 1

A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China

CompletedNCT04477772

Shanghai Junshi Bioscience Co., Ltd.Recurrent/Refractory Malignant Lymphoma

Start: 2020-07-17End: 2024-03-14Updated: 2024-05-16

The Safety and Efficacy of Multiple-dose of JS004 in Subject With HNC

CompletedNCT04929080

Shanghai Junshi Bioscience Co., Ltd.Head and Neck Squamous Cell Carcinom, Nasopharyngeal Carcinoma

Start: 2021-05-11End: 2023-03-06Updated: 2023-08-01

Related Papers

Tifcemalimab as monotherapy or in combination with toripalimab in patients with relapsed/refractory lymphoma: a Phase I trial.

2025-05-161 citations

Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

Blood2023-11-02

Phase I Study of the Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas

Blood2022-11-1512 citations

Phase I study of the anti-BTLA antibody icatolimab as a single agent or in combination with toripalimab in relapsed/refractory lymphomas.

Journal of Clinical Oncology2022-06-015 citations